Endothelial cells line the blood vessels and are fundamental to the functioning of the cardiovascular system. They regulate the movement of substances and fluid between the bloodstream and surrounding tissues. Disruption of the endothelial barrier can lead to severe consequences, including increased vascular permeability, allowing harmful substances to enter tissues, which may result in various diseases including cardiovascular conditions, diabetes, and cancer. Understanding how G3BP1 contributes to endothelial barrier integrity may offer new avenues for therapeutic intervention.

The first mechanism by which G3BP1 supports the endothelial barrier is through the stabilization of mRNAs that encode junctional proteins. These proteins are vital for maintaining tight junctions between endothelial cells, which are the key structures that control permeability. The researchers demonstrated that G3BP1 binds to mRNA transcripts of these junction proteins, thus preventing their degradation and ensuring a healthy supply of these critical components. This stabilization is essential for the proper assembly and maintenance of the endothelial barrier, suggesting that G3BP1 is a key player in orchestrating a protective response against environmental stressors.

Moreover, the second mechanism highlights G3BP1’s ability to suppress an inflammatory signaling pathway that can compromise endothelial barrier integrity. The MYD88-ARNO-ARF6 pathway is known to promote inflammation within endothelial cells, thereby disrupting the careful regulation of permeability. The study provides compelling evidence that G3BP1 inhibits this pathway, thereby preventing inflammatory signals from triggering increased permeability. This dual action of stabilization of protective proteins along with suppression of destructive signaling presents a comprehensive strategy that cells may employ to safeguard themselves against threats.

The implications of these findings are immense, especially considering that inflammation is a common underlying factor in a plethora of diseases. By targeting the G3BP1 pathway, researchers may develop novel therapeutic strategies to strengthen the endothelial barrier during inflammation, potentially reducing the risk of diseases that stem from barrier dysfunction. This research positions G3BP1 as a promising candidate for future drug development aimed at enhancing vascular health.

Breaking down the intricacies of the G3BP1’s function reveals a tightly regulated system wherein the stability of junctional proteins balances the inflammatory responses that endothelial cells face in pathological conditions. Chronic inflammation often leads to endothelial dysfunction, where the normal barrier functions are compromised, promoting vascular diseases. The researchers suggest that enhancing the activity of G3BP1 or mimicking its functions could be a therapeutic avenue worth exploring.

Clinical studies will be necessary to validate the potential of G3BP1 as a therapeutic target. Researchers are especially interested in examining the effects of modulating G3BP1 levels in both animal models and human patients. If G3BP1 can be shown to not only maintain but also restore endothelial barrier integrity during inflammatory states, it may lead to significant advancements in the treatment of inflammatory diseases and conditions characterized by vascular permeability.

The study also raises intriguing questions about the regulation of G3BP1 itself. Understanding what triggers its expression and activity could provide insight into how the body naturally responds to inflammatory stimuli. There is much to learn about the upstream regulators of G3BP1 and how environmental factors influence its function. Deciphering these regulatory mechanisms could unveil targets for pharmacological intervention.

This research signifies a crucial step towards a more nuanced understanding of the endothelial barrier’s biological processes. The dual role of G3BP1 underscores a more sophisticated level of control within the cellular environment, where protection against inflammation is just as crucial as maintaining structural integrity. Developing a deeper understanding of such proteins can highlight not only their relevance in health but also in the mechanisms of diseases such as atherosclerosis, where endothelial barrier dysfunction plays a significant role.

As further studies unfold, the scientific community is eager to witness the full scope of G3BP1’s capabilities within the vascular system. Clarifying its roles in different cellular contexts could help bridge the gap between laboratory research and clinical application. Future findings may promote the exploration of this protein beyond endothelial cells, potentially influencing research in other tissue types that encounter similar issues of permeability and inflammation.

Overall, the findings presented in this study lay a critical foundation for future research into endothelial biology. The potential for targeting G3BP1 seeks to reshape our approach to treating diseases characterized by inflammation and vascular dysfunction. By tapping into the natural mechanisms of cellular integrity already present within our bodies, scientists hope to turn the tide against diseases that result from barriers that are too easily compromised.

The ongoing exploration of G3BP1 and its pathways provides a source of optimism within the scientific community, emphasizing the importance of understanding fundamental biological mechanisms to innovate therapeutic strategies. As our knowledge expands, it is anticipated that these insights will lead to novel treatment strategies that can profoundly impact patient care in vascular-related diseases.

The commitment to uncovering the intricate roles of proteins like G3BP1 underlines the evolving landscape of biomedical research, where the focus is increasingly on molecular players that may hold the keys to understanding and treating complex health challenges. The future of endothelial barrier research looks bright as scientists continue to explore the depths of molecular interactions and the effects they have on human health.

Subject of Research: G3BP1 and Endothelial Barrier Integrity

Article Title: G3BP1 maintains endothelial barrier integrity through dual mechanisms: direct stabilization of junction protein mRNAs and suppression of the inflammatory MYD88-ARNO-ARF6 pathway.

Article References:
Sun, W., Wu, H., He, Y. et al. G3BP1 maintains endothelial barrier integrity through dual mechanisms: direct stabilization of junction protein mRNAs and suppression of the inflammatory MYD88-ARNO-ARF6 pathway.
Angiogenesis 28, 46 (2025). https://doi.org/10.1007/s10456-025-09993-5

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10456-025-09993-5

Keywords: G3BP1, Endothelial Barrier, Junction Proteins, Inflammation, MYD88-ARNO-ARF6 Pathway, Vascular Health, Therapeutic Target.

When platelets encounter vascular injury, they are activated and aggregate to form an initial blood clot. However, under certain pathological conditions, they can enter a hyper-activated state known as procoagulant activation. This state exhibits distinct features that not only enhance clot formation but also broaden the scope of platelet involvement in pathological processes beyond clotting. Procoagulant platelets expose phosphatidylserine on their surfaces, leading to a pro-inflammatory microenvironment that can exacerbate cardiovascular conditions.

One of the key aspects of procoagulant platelets is their ability to interact with various inflammatory mediators and cellular components of the immune system. This interaction plays a significant role in the pathophysiology of atherosclerosis, where chronic inflammation contributes to plaque instability and rupture. Procoagulant activation may increase the risk of thrombus formation in atherosclerotic lesions, highlighting the dual role of platelets in both promoting clot formation and fueling inflammation.

Research over the past decade has laid the groundwork for understanding the signaling pathways that mediate procoagulant platelet activation. These pathways involve various receptors, including glycoprotein receptors, Toll-like receptors, and integrins, which respond to different stimuli such as thrombin, collagen, and lipopolysaccharides. The activation of these receptors leads to intracellular signaling cascades, ultimately resulting in a procoagulant phenotype that is distinct from the traditional platelet aggregation response.

What sets procoagulant platelets apart from their aggregatory counterparts is their unique surface characteristics and functional engagement. In addition to the exposure of phosphatidylserine, procoagulant platelets also release significant amounts of cytokines and chemokines, further amplifying the inflammatory response and interacting with other immune cells. This cross-talk suggests that platelets do not work in isolation; instead, they operate within a complex network of cellular and molecular interactions that ultimately dictate the outcomes in cardiovascular diseases.

The clinical implications of procoagulant platelets cannot be overstated. Their involvement in thromboinflammatory processes positions them as potential biomarkers and therapeutic targets for a range of cardiovascular conditions. For instance, measuring levels of activated platelets, or specific procoagulant markers, could provide valuable insights into a patient’s risk profile for thrombotic events. Moreover, interventions aimed at modulating platelet activity may have therapeutic benefits, especially in high-risk populations prone to thromboembolic complications.

As research advances, there is potential for developing novel therapeutic strategies that can specifically inhibit the procoagulant state of platelets. Existing anticoagulants may not target this specific pathway effectively, leaving a gap for innovative treatment options. Future studies could investigate the feasibility of using monoclonal antibodies that target specific platelet receptors implicated in procoagulant activation, or small molecules that inhibit the associated signaling pathways.

Furthermore, the connection between procoagulant platelets and immune-mediated diseases opens up avenues for broader research horizons. Conditions characterized by excessive inflammation, such as septic shock or autoimmune disorders, could potentially benefit from insights gained regarding procoagulant platelets. Understanding how these platelets interact with immune complexes may lead to better management strategies for patients facing such multi-faceted health challenges.

The exploration of procoagulant platelets is an exciting frontier in cardiovascular research, reflecting a shift towards holistic approaches in understanding disease mechanisms. As we continue to uncover the multifaceted roles these cells play in health and disease, it becomes increasingly clear that the intersection of thrombosis and inflammation holds the keys to new therapeutic possibilities. Continued funding and focus on this research area are essential, as a deeper understanding of platelet biology could revolutionize the way we approach cardiovascular disease management.

In summary, procoagulant platelets represent a dynamic intersection between hemostasis, thrombosis, and inflammation. Their unique activation state provides insights into the mechanisms underpinning not only cardiovascular diseases but also a broad spectrum of inflammatory conditions. With ongoing research, we may unlock new potential in diagnostics and therapeutics, translating advances in platelet biology into improved patient outcomes.

Subject of Research: Procoagulant platelets in cardiovascular disease

Article Title: Procoagulant platelets: linking coagulation and thromboinflammation in cardiovascular disease.

Article References: Kaiser, R., Nicolai, L. Procoagulant platelets: linking coagulation and thromboinflammation in cardiovascular disease. Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01250-6

Image Credits: AI Generated

DOI:

Keywords: Procoagulant platelets, thrombosis, inflammation, cardiovascular disease, signaling pathways, therapeutic targets, myocardial infarction, stroke, deep vein thrombosis.

Lipid homeostasis is essential for maintaining cellular integrity and functionality. Disruptions in lipid metabolism can lead to serious health conditions, such as obesity, metabolic syndrome, and cardiovascular diseases. The regulation of lipids within cellular membranes is a finely tuned process that requires intricate interactions between various enzymes, proteins, and lipids themselves. Despite its significance, the mechanisms that underpin lipid homeostasis remain poorly understood, a gap that this new research aims to bridge.

The team’s innovative methodology integrates proximity labeling with membrane editing to manipulate and identify proteins involved in lipid metabolism. Proximity labeling is a technique that allows researchers to tag proteins that are in close proximity to a specific target protein, providing a snapshot of the molecular interactions occurring within the cellular environment. By applying this technique to lipid-rich membranes, the researchers were able to reveal a host of previously unidentified regulatory proteins that play crucial roles in lipid metabolism.

In their study, the researchers utilized a modified version of the proximity labeling technique, enabling the selective tagging of proteins associated with specific lipid species within cellular membranes. This targeted approach allows for a more precise dissection of the protein-lipid interactions that regulate lipid homeostasis. The ability to visualize and analyze these interactions in real-time offers a revolutionary insight into how cells maintain lipid balance under various physiological conditions.

One of the pivotal discoveries from this study was the identification of a set of novel lipid-binding proteins that had previously gone unnoticed. These proteins, which display affinity for specific lipid species, may provide vital clues into the pathways that regulate lipid synthesis, storage, and degradation. The significance of these findings extends beyond basic science, as they could inform future drug development aimed at addressing metabolic disorders linked to lipid imbalances.

The researchers employed a combination of advanced imaging techniques and biochemical assays to validate their findings. The incorporation of high-resolution microscopy allowed the team to visualize the dynamics of lipid distribution within cellular membranes. Coupled with mass spectrometry, these techniques enabled the researchers to analyze complex lipid profiles and elucidate the roles of identified proteins in lipid regulation.

Furthermore, the study highlights the importance of cellular context in understanding lipid homeostasis. The researchers demonstrated that lipid metabolism is not a static process but rather a dynamic interplay of various factors that can differ dramatically across different cell types and physiological conditions. This underscores the need for a multifaceted approach to studying lipid homeostasis, one that takes into account the complexities inherent in cellular environments.

In the realm of therapeutic applications, the implications of this study are profound. By identifying key regulatory proteins involved in lipid homeostasis, researchers may pave the way for the development of targeted therapies aimed at correcting lipid imbalances. Such advancements could lead to novel treatments for metabolic diseases that afflict millions worldwide, offering hope to patients struggling with conditions that currently lack effective interventions.

The findings from this study also encourage further exploration into the role of lipid metabolism in processes beyond traditional metabolic disorders. Researchers are beginning to uncover links between lipid homeostasis and neurodegenerative diseases, highlighting the intricate relationships between lipids and brain health. By deepening our understanding of these connections, future research may uncover new pathways for intervention in a range of health issues.

Moreover, the technique of membrane editing with proximity labeling itself stands to revolutionize the field of cell biology. Its applications could extend well beyond lipid metabolism, enabling researchers to investigate the myriad of protein interactions that underpin cellular functions across different biological systems. The potential for discovering new therapeutic targets that arise from this technique could lead to a paradigm shift in how we approach complex diseases.

As this research gains traction, it emphasizes the critical role of interdisciplinary collaboration in scientific advancement. The integration of molecular biology, biophysics, and computational analysis has allowed the team to push the boundaries of what is possible in the study of lipid biology. Such collaborative efforts will be essential as we continue to navigate the complexities of cellular metabolism and its implications for human health.

In conclusion, the study by Tei et al. represents a significant step forward in our understanding of lipid homeostasis and its regulation. By leveraging innovative techniques such as membrane editing with proximity labeling, researchers are illuminating the complex web of interactions that govern lipid metabolism. This research not only provides valuable insights into cellular biology but also lays the foundation for future explorations into therapeutic interventions for metabolic disorders and beyond.

As science continues to evolve, it is imperative that researchers remain committed to unraveling the complexities of lipid biology. This pioneering work serves as a testament to the power of innovation in the quest for knowledge and highlights the importance of dedication and collaboration in tackling the pressing health challenges of our time.

With the publication of this research, we may be at the cusp of a new era in lipid research, one that holds great promise for transforming our approach to understanding and treating diseases linked to lipid metabolism. The findings serve as a call to action for the scientific community to delve deeper into this fascinating field and encourage a continued commitment to harnessing the tools of modern science in the pursuit of improved health outcomes for all.

In summary, as researchers advocate for further studies, the urgency in understanding lipid homeostasis remains paramount. The revelations presented in this groundbreaking study may very well mark the beginning of a new chapter in our understanding of lipid biology, one that may lead us toward innovative strategies for combating metabolic diseases and ultimately improving health globally.

Subject of Research: Lipid homeostasis regulation

Article Title: Membrane editing with proximity labeling reveals regulators of lipid homeostasis

Article References:

Tei, R., Li, XL., Luan, L. et al. Membrane editing with proximity labeling reveals regulators of lipid homeostasis.
Nat Chem Biol (2026). https://doi.org/10.1038/s41589-025-02104-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41589-025-02104-x

Keywords: Lipid metabolism, proximity labeling, membrane editing, lipid homeostasis, regulatory proteins, metabolic disorders.

High-altitude pulmonary hypertension is a pathological condition characterized by elevated blood pressure in the pulmonary arteries, triggered by the reduced oxygen levels found in higher altitudes. While the body typically adapts to lower oxygen concentrations through physiological changes, some individuals experience maladaptive responses, leading to HAPH. These maladaptive responses can result in symptoms such as shortness of breath, fatigue, and even heart failure, underscoring the urgent need for effective therapeutic strategies.

At the core of this research is the protein PHPT1, which has emerged as a key player in regulating cellular responses to hypoxia, or low oxygen levels. Prior studies have hinted at the potential roles of various proteins in HAPH, but the specific mechanisms remained elusive. This new study sets a precedent by demonstrating how PHPT1 functions as an inhibitor of HAPH through its effects on TRPV5, a calcium channel known for its roles in cellular signaling pathways. By negatively regulating TRPV5, PHPT1 appears to modulate the growth of pulmonary vasculature, offering a pathway for therapeutic intervention.

The researchers embarked on a comprehensive investigation to understand the intricate relationship between PHPT1 and TRPV5. This involved a series of in vitro and in vivo experiments, leading to crucial insights into how manipulating PHPT1 levels can influence pulmonary arterial pressure. The evidence presented in this study suggests that heightened PHPT1 activity reduces TRPV5 expression, thereby alleviating the pathological remodeling of pulmonary arteries commonly seen in HAPH.

One of the most striking findings from the study was the identification of the signaling pathways intertwined with PHPT1 and TRPV5. The team utilized advanced molecular biology techniques, including CRISPR gene editing, to dissect the specific roles each molecule plays in cellular signaling. By elucidating these pathways, they painted a clearer picture of the biological responses elicited by low oxygen environments and how PHPT1 can tip the balance towards protective mechanisms.

The potential for developing targeted therapies based on these findings is monumental. As researchers look towards pharmacological interventions, the focus on PHPT1 as a therapeutic target could lead to the development of novel treatments that specifically modulate its activity. This is particularly exciting given the limited options currently available for patients suffering from HAPH. The hope is that by harnessing the inhibitory effects of PHPT1 on TRPV5, clinicians can create personalized approaches that improve patient outcomes.

Moreover, the implications of this research extend beyond understanding HAPH alone. The role of calcium channels, and particularly TRPV5, has been a point of interest in various other cardiovascular diseases. By delineating the functional relationships between PHPT1 and TRPV5, this study opens new avenues not just in research but also in the clinical setting, potentially leading to breakthroughs in managing conditions that stem from calcium signaling disruptions.

While these findings position PHPT1 as a prominent player in HAPH, it also raises further questions regarding its expression in different populations and altitudinal adaptations. Future studies will need to address how genetic variations impact PHPT1 activity and TRPV5 regulation across diverse populations, revealing crucial insights that could help in the development of universal treatment modalities.

The researchers’ next steps will likely involve clinical trials, aimed at validating their preclinical findings in human subjects. By observing how modulation of PHPT1 affects HAPH in real-world conditions, they hope to create a comprehensive treatment protocol that is not only effective but also safe for a broad patient demographic.

In summary, the study by Guo and colleagues heralds a significant advancement in our understanding of high-altitude pulmonary hypertension. By unveiling the role of PHPT1 as an inhibitory regulator through negative signaling via TRPV5, they have set a stage ripe for therapeutic innovation. As the scientific community keenly anticipates further developments, the potential for this new knowledge to transform treatment strategies for HAPH is undeniably promising.

Understanding high-altitude pulmonary hypertension requires a multifaceted approach that considers genetic factors, environmental influences, and individual physiological responses. The work of these researchers exemplifies how detailed molecular insights can inform and enhance clinical practices. As we continue to traverse into uncharted territories of genetic and environmental interactions, studies like this will remain pivotal in steering both our scientific understanding and treatment paradigms towards new horizons.

Embracing an integrative perspective will allow future research to build upon these foundational findings. As pathophysiological mechanisms become clearer, the possibility of providing targeted and effective treatments to vulnerable populations becomes increasingly tangible. With every advancement in this field, we inch closer to alleviating the burdens placed on individuals suffering from high-altitude pulmonary hypertension and chronic respiratory illnesses.

In conclusion, the study conducted by Guo, Zhu, and Xu marks a formidable leap forward in the understanding of HAPH. Their innovative exploration into the dynamics of PHPT1 and TRPV5 establishes new connections that promise to revolutionize our therapeutic approaches and ultimately save lives. As further investigations unfold, the medical community eagerly looks forward to the translation of these findings into clinical practice.

Subject of Research: High-Altitude Pulmonary Hypertension

Article Title: PHPT1 acts as an inhibitor in high-altitude pulmonary hypertension via negative TRPV5 signaling regulation

Article References:

Guo, G., Zhu, Mx., Xu, X. et al. PHPT1 acts as an inhibitor in high-altitude pulmonary hypertension via negative TRPV5 signaling regulation.J Transl Med 23, 968 (2025). https://doi.org/10.1186/s12967-025-06980-8

Image Credits: AI Generated

DOI: 10.1186/s12967-025-06980-8

Keywords: High-altitude pulmonary hypertension, PHPT1, TRPV5, signaling pathways, therapeutic targets

At the forefront of this significant research are Zachary Berndsen and Keith Cassidy, both specialists in cryo-electron microscopy, a cutting-edge technique that visualizes the three-dimensional structures of biological entities with unparalleled resolution. Their work has synthesized the latest advancements in microscopy with artificial intelligence, shedding light on the previously enigmatic nature of ApoB100 and its relationship with LDL particles. By accurately depicting the shape and form of ApoB100, the study not only enhances our understanding of lipid metabolism but also identifies potential therapeutic targets, offering hope for the development of more precise cholesterol-lowering medications.

The study’s approach employed state-of-the-art cryo-electron microscopy, which allows scientists to observe biological molecules at extraordinarily high magnifications, revealing intricate details previously thought unattainable. This technology diverges from traditional optical methods, as it enables researchers to visualize proteins and their complexes in their native states, thus providing a clearer understanding of their functionalities. Berndsen articulated the significance of cryo-electron microscopy in translating the complexities of molecular biology into tangible data, remarking on its potential to revolutionize scientific discovery by offering insights into structures that are thousands of times smaller than the dimensions of an average cell.

The quest to comprehend ApoB100 commenced with Berndsen’s meticulous analysis using a remarkably large cryo-electron microscope, allowing a close examination of the protein’s structural attributes. Following this, Cassidy, utilizing the computational power of Mizzou’s advanced supercomputing resources, including the Hellbender system, integrated artificial intelligence to refine the visualization of ApoB100. By employing the AI neural network AlphaFold in tandem with the cryo-electron microscopy data, Cassidy achieved a remarkably detailed characterization of the protein’s conformation, thus enriching the framework for understanding how ApoB100 interacts with LDL particles when navigating through the circulatory system.

Cholesterol, which is often vilified due to its association with cardiovascular diseases, plays an indispensable role in the human body, participating in numerous physiological processes. This includes the synthesis of hormones and the maintenance of cell membrane integrity and fluidity, as emphasized by Cassidy in his commentary about the dual nature of cholesterol. Understanding ApoB100’s structure permits researchers to appreciate how it campaigns alongside LDL in the bloodstream and its implications for cardiovascular health, enabling the design of pharmacotherapies that can modulate cholesterol levels without compromising its beneficial roles.

The implications of this study extend well beyond a mere academic pursuit, embodying a practical aspect that addresses real-world health challenges. Currently, prevalent methods for evaluating cholesterol levels lack specificity, potentially leading to misdiagnoses which can exacerbate health issues. Berndsen advocates for a paradigm shift towards measuring ApoB100 concentrations in the bloodstream, which could serve as a more reliable predictor for heart disease risk. By developing assays that target ApoB100 specifically, clinicians may enhance early detection efforts for at-risk patients, thus improving preventative care strategies against cardiovascular diseases.

Furthermore, this research is underscored by a personal motivation; both Berndsen and Cassidy have familial ties to cardiovascular illnesses. Their professional endeavors are powered not only by scientific curiosity but also a passionate resolve to contribute to a larger societal good. The dual commitment to advancing basic science while simultaneously bridging the gap towards tangible health improvements illustrates the invaluable role of researchers in shaping public health outcomes.

Ultimately, the innovative approach employed in this study signifies a considerable leap forward in lipid research. By unraveling the intricate structure of ApoB100 and elucidating its biological context, researchers have set a foundation upon which future therapies can be cultivated. This interplay between advanced microscopy and computational models serves as a prototype for a new wave of research strategies that could significantly enhance our understanding of protein interactions at the molecular level.

As the scientific community stands on the shoulders of such revelations, there is renewed optimism that the next generation of cholesterol medications will not only lower LDL levels more effectively but also sidestep the adverse side effects that have beleaguered existing treatments. The successful integration of precision medicine principles with basic biochemical research heralds a transformative era in cardiovascular therapy, informed by the structural insights gained into proteins like ApoB100 and their role within cellular networks.

Thus, the journey does not end with the mere discovery of ApoB100’s structure; it marks the commencement of extensive research efforts aimed at translating this knowledge into impactful health solutions. As researchers like Berndsen and Cassidy continue to explore the complexities of cholesterol metabolism armed with advanced tools and methodologies, there exists a promising horizon of advancements that could very well redefine how we approach heart disease and cholesterol management in the coming years. With this significant stride in understanding lipoprotein functions, the roadmap toward more effective cardiovascular treatments is being meticulously laid out.

In conclusion, the findings regarding the structure of ApoB100 not only augment existing biomedical knowledge but also hold the potential to revolutionize the landscape of cardiovascular therapeutics. As the implications of this research unfold, it beckons a future where personalized and precise cholesterol-lowering therapies become a reality, ultimately improving the health and longevity of individuals standing at the precipice of heart disease.

Subject of Research: Structure of ApoB100 and its implications for LDL and cardiovascular health
Article Title: The structure of apolipoprotein B100 from human low-density lipoprotein
News Publication Date: 11-Dec-2024
Web References: Nature Article
References: DOI: 10.1038/s41586-024-08467-w
Image Credits: Credit: University of Missouri

Keywords

Low-density lipoproteins, ApoB100, cardiovascular research, cryo-electron microscopy, artificial intelligence, cholesterol, heart disease, targeted therapies, lipid metabolism, molecular structure, precision medicine, public health.